Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Kerry’s BC30 Probiotic Linked to GLP-1 Medication Support Benefits: Consumer Survey - Nutraceuticals World

What are you searching for?

Sign in
Products & Ingredients, Research

Kerry’s BC30 Probiotic Linked to GLP-1 Medication Support Benefits: Consumer Survey

GLP-1 drug users reported that BC30 was linked to improvements in daily quality of life, adherence to medication, and digestive health.

Author Image

By: Mike Montemarano

Associate Editor, Nutraceuticals World

Photo: alones | Adobe Stock

A new consumer survey found that a probiotic marketed as BC30 by Kerry Group was associated with improvements in self-reported digestive health and quality of life measures in people using GLP-1 medications for weight management or type 2 diabetes.

The four-week, open-label, uncontrolled consumer perception study tested whether the probiotic, which had been evidenced in previous clinical research to improve digestive symptoms, would have similar effects in a real-world context among people on GLP-1 drugs.

After four weeks of using BC30:

  • 77% of participants perceived a moderate to significant improvement in overall daily quality of life, which was previously impacted by GI symptoms;
  • 60% of participants found BC30 to be moderately to very useful in improving digestive health, while 12% perceived it as a “game changer”;
  • Over 80% of participants noted an improvement in GI symptoms, with those symptoms either completely disappearing or at least feeling better;
  • 69% of participants indicated they would continue using GLP-1 medications due to BC30’s positive effect on GI discomfort and overall health;
  • 66% indicated they would purchase BC30, 91% indicated they would recommend it to other GLP-1 medication users, and 41% rated it as “fantastic.”

Whlie 30-35% of Americans are interested in taking GLP-1 drugs, 50-75% of users discontinue use of the drug within a year, and before meeting their weight management goals, often due to digestive and other side effects.

“Gastrointestinal issues are among the main drivers of a reduced quality of life and one of the key reasons consumers abandon weight management treatment with GLP-1 medications,” said Alexandra Boelrijik, global RD&A vice president at Kerry. “Although several products in the marketplace claim to support digestive issues, few have necessarily been evaluated and tested by a consumer population of GLP-1 medication users. This population reported enhanced GI comfort and improved quality of life after consuming BC30 for four weeks. BC30 is a highly stable, science-backed formulation, that can be used in a variety of enhanced food and beverages which can fit seamlessly into consumer routines and changing eating habits.”

To learn more, Kerry will be hosting a webinar on June 25, which will dive into key findings from the research, reasons GLP-1 drug users discontinue treatment, and more.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Topics